.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
McKesson
Cerilliant
Argus Health
Teva
Baxter
Daiichi Sankyo
Fish and Richardson
Express Scripts
UBS

Generated: September 23, 2017

DrugPatentWatch Database Preview

Acadia Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ACADIA PHARMS INC, and when can generic versions of ACADIA PHARMS INC drugs launch?

ACADIA PHARMS INC has one approved drug.

There are thirteen US patents protecting ACADIA PHARMS INC drugs.

There are one hundred and twenty-nine patent family members on ACADIA PHARMS INC drugs in twenty-seven countries.

Summary for Applicant: Acadia Pharms Inc

Patents:13
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Acadia Pharms Inc
NUPLAZID
pimavanserin tartrate
TABLET;ORAL207318-001Apr 29, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Acadia Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,790,899Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)ph- enylmethyl)carbamide and its tartrate salt and crystalline forms► Subscribe
2,017,165,273► Subscribe
7,732,462Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,868,176Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N'-(4-(2-methylprop- yloxy)phenylmethyl)carbamide and their preparation► Subscribe
7,713,995Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
7,393,861Derivatives of 4-aminopiperidine and their use as a medicament► Subscribe
9,211,289Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
8,227,487Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
8,377,959Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
8,008,323Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Acadia Pharms Inc Drugs

Country Document Number Estimated Expiration
European Patent Office1787984► Subscribe
Portugal1587789► Subscribe
Canada2580136► Subscribe
Slovenia1794126► Subscribe
South Korea20070014235► Subscribe
Poland356365► Subscribe
Hungary0204515► Subscribe
BrazilPI0516063► Subscribe
Portugal1286966► Subscribe
Australia2005202257► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Covington
Julphar
Johnson and Johnson
Moodys
Medtronic
McKesson
Merck
Healthtrust
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot